View in EDS

Impact of simulated reduced injected dose on the assessment of amyloid PET scans

Saved in:
Bibliographic Details
Title: Impact of simulated reduced injected dose on the assessment of amyloid PET scans
Authors: Young, Peter, Heeman, Fiona, Axelsson, Jan, Collij, Lyduine E., Hitzel, Anne, Sanaat, Amirhossein, Niñerola-Baizan, Aida, Perissinotti, Andrés, Lubberink, Mark, Frisoni, Giovanni, Zaidi, Habib, Barkhof, Frederik, Farrar, Gill, Baker, Suzanne, Gispert, Juan Domingo, Garibotto, Valentina, Rieckmann, Anna, Schöll, Michael, on behalf of the AMYPAD consortium
Source: Eur J Nucl Med Mol Imaging
Young, P, Heeman, F, Axelsson, J, Collij, L E, Hitzel, A, Sanaat, A, Niñerola-Baizan, A, Perissinotti, A, Lubberink, M, Frisoni, G B, Zaidi, H, Barkhof, F, Farrar, G, Baker, S, Gispert, J D, Garibotto, V, Rieckmann, A & Schöll, M 2023, 'Impact of simulated reduced injected dose on the assessment of amyloid PET scans', European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06481-0
European journal of nuclear medicine, vol 51, iss 3
Publisher Information: Springer Science and Business Media LLC, 2023.
Publication Year: 2023
Subject Terms: Amyloid, 616.8, Radiology and Medical Imaging, Alzheimer Disease/diagnostic imaging, Dose reduction, Neuroimaging, Amyloid/metabolism, 618.97, Alzheimer Disease, Flutemetamol, Amyloid/metabolism [MeSH], Benzothiazoles [MeSH], Amyloid beta-Peptides/metabolism [MeSH], Humans [MeSH], Aniline Compounds [MeSH], Alzheimer Disease/diagnostic imaging [MeSH], PET, Alzheimer's disease, Original Article, Positron-Emission Tomography/methods [MeSH], Brain/metabolism [MeSH], Stilbenes [MeSH], Stilbenes, Brain/metabolism, Humans, Benzothiazoles, Amyloid beta-Peptides/metabolism, 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene, Amyloid / metabolism, Positron-Emission Tomography / methods, Aniline Compounds, Amyloid beta-Peptides, 616.0757, Amyloid beta-Peptides / metabolism, Brain, Positron-Emission Tomography/methods, 3. Good health, Positron-Emission Tomography, Brain / metabolism, Radiologi och bildbehandling, Alzheimer Disease / diagnostic imaging, Radiology, Nuclear Medicine and Medical Imaging
Description: Purpose To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90–110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated. Results At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [18F]flutemetamol and [18F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were 80% for both tracers. Conclusion This proof-of-concept study showed that for both [18F]flutemetamol and [18F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances.
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 1619-7089
1619-7070
DOI: 10.1007/s00259-023-06481-0
Access URL: https://pubmed.ncbi.nlm.nih.gov/37897616
https://hdl.handle.net/11370/aa551d4b-0737-4f9d-be1d-90843af726a0
https://doi.org/10.1007/s00259-023-06481-0
https://research.rug.nl/en/publications/aa551d4b-0737-4f9d-be1d-90843af726a0
https://research.vumc.nl/en/publications/9b5cef21-a9fd-4d37-9dce-d380a8bb0adb
https://pure.amsterdamumc.nl/en/publications/37aabcfd-b105-4e44-8898-abb62e36058c
https://doi.org/10.1007/s00259-023-06481-0
https://repository.publisso.de/resource/frl:6522464
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-216200
https://discovery-pp.ucl.ac.uk/id/eprint/10180213/
https://escholarship.org/uc/item/839107h6
https://escholarship.org/content/qt839107h6/qt839107h6.pdf
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-521120
Rights: CC BY
Accession Number: edsair.doi.dedup.....d55b61c8f35b563a9b4bfab5fdae1e6c
Database: OpenAIRE
Description
Abstract:Purpose To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90–110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for Aβ-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between Aβ- and Aβ + scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated. Results At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [18F]flutemetamol and [18F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were 80% for both tracers. Conclusion This proof-of-concept study showed that for both [18F]flutemetamol and [18F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances.
ISSN:16197089
16197070
DOI:10.1007/s00259-023-06481-0